mRNA Technology Newsletter
Issue #63November 16, 20267 studies

Spray-dried mRNA vaccine powder stays potent in the fridge for 3 years

The biggest logistical headache in mRNA medicine isn't the science—it's the freezer.

A new delivery format sidesteps ultra-cold storage entirely, and it's just one of several ideas this week quietly rewriting what mRNA can do.

🧊 No Freezer Required: mRNA Vaccines That Last 3 Years in the Fridge

  • The researchers tested whether an experimental dry vaccine formulation retained activity during refrigerated storage.
  • The powder held its potency—colloidal stability, mRNA integrity, and biological activity—for over 3 years under refrigerated conditions. Liquid formulations showed substantial degradation within 6–9 months under the same conditions.
  • The investigators compared the stored product with a liquid formulation in preclinical tests.

Why it matters: A vaccine that can use existing refrigerators could be easier to distribute. Clinical studies would need to establish its performance in people.

🥈 Top 2% journal 🔗 Advanced science (Weinheim, Baden-Wurttemberg, Germany) Journal Article 🗓️ Nov 10

Key Findings

🤖 AI Picks Better Lipid Nanoparticles—Then Proves It in Mice

  • Starting from a 520-compound library, researchers trained a machine learning model on cell-based transfection data, then used it to virtually screen 10,920 candidate lipids. The top pick, PA97MD101, delivered mRNA to mouse livers more effectively than standard formulations and successfully silenced a disease-relevant gene via CRISPR.
  • The researchers compared their predictions with experimental measurements, including results from mice.
💡 Interpretable AI cut lipid nanoparticle discovery from guesswork to guided search.
🥈 Top 2% journal 🔗 Nature communications Journal Article 🗓️ Nov 9

❤️ mRNA Prompts Mouse Hearts to Regenerate After a Heart Attack

  • A modified mRNA encoding two proteins—Myc and cyclin T1—triggered adult cardiomyocytes to divide and replace lost tissue after myocardial infarction in mice. Adult mammalian hearts normally lack this capacity entirely.
  • Critically, the effect required only transient expression. Sustained activation caused problems; the brief mRNA pulse was enough to drive repair and functional recovery.
💡 Transient mRNA expression, not permanent gene change, was enough to rebuild heart muscle.
🥈 Top 2% journal 🔗 Nature cardiovascular research Journal Article 🗓️ Nov 9

🫁 Lung-Targeting Nanoparticles Cut Fibrosis Scarring by ~40% in Mice

  • Researchers evaluated an experimental mRNA treatment for lung fibrosis in mice.
  • Treated mice showed approximately 40% less collagen deposition by histology and significantly reduced hydroxyproline content—a direct marker of fibrotic scarring.
💡 Organ-targeted RNA delivery reached the fibrotic cells that matter most.
🔗 J Control Release Journal Article 🗓️ Nov 10

💉 New Moderna Vaccine Outperforms Pfizer's in Older Veterans

  • A comparative effectiveness study in older US veterans during the 2025–2026 respiratory season found that mRNA-1283, Moderna's newer vaccine targeting immunodominant spike regions, provided higher estimated protection against severe COVID-19 than BNT162b2.
  • This is the first real-world effectiveness data for mRNA-1283 in an older adult population, a group that remains at elevated risk for severe outcomes.
💡 Next-generation mRNA vaccine design translated into measurable real-world protection gains.
🥈 Top 2% journal 🔗 JAMA network open Comparative Study 🗓️ Nov 11

🦟 One mRNA Vaccine Targets Both Zika and Dengue—Without the Backfire Risk

  • A bispecific mRNA vaccine combined a Zika neutralizing antibody module with conserved T-cell epitopes from both Zika and dengue. The design deliberately separated the antibody-generating and T-cell-generating components to avoid antibody-dependent enhancement—the phenomenon where cross-reactive antibodies can worsen dengue infection.
  • In immunodeficient mice, the vaccine protected against challenge from both viruses and produced neutralizing antibody titers up to 8-fold higher than an unadjuvanted comparison.
💡 Splitting immune targets by function may solve the Zika-dengue cross-reactivity problem.
🥉 Top 5% journal 🔗 Emerging microbes & infections Journal Article 🗓️ Nov 10

🧫 mRNA Converts Stem Cells to Blood Vessel Cells at 97% Efficiency

  • Ionizable lipid nanoparticles delivered mRNA encoding a single transcription factor to human pluripotent stem cells, converting more than 97% of cells and generating endothelial cell populations with average purities above 90%—without any genome integration.
  • The approach worked across a wide range of cell densities and mRNA doses, suggesting the process is robust enough to scale for tissue engineering or cell therapy manufacturing.
💡 Near-complete stem cell conversion via transient mRNA—no permanent genetic modification needed.
🥉 Top 5% journal 🔗 Acta biomaterialia Journal Article 🗓️ Nov 13

Implications

mRNA platforms are converging on the same unsolved problem from multiple angles: getting the right molecule to the right cell outside the liver, at the right time, without triggering the immune system on repeat doses. The powder stability and lung-targeting results narrow the delivery gap—but whether any of these formats can reach non-liver tissues reliably in humans remains the open question.

Studies in this issue

Primary sources used for this newsletter.

  1. Spray-Dried mRNA Nanoparticle Powder for Multiple Delivery Methods with 3-Year Stability in the Fridge
    main storyAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-11-10PMID 43006795
  2. Temporary mRNA carrying Myc and cyclin T1 improves heart function after injury
    key findingNature cardiovascular research2026-11-09PMID 43003910
  3. Lipid nanoparticles that target lungs deliver SMAD7 mRNA to reduce lung scarring
    key findingJournal of controlled release : official journal of the Controlled Release Society2026-11-10PMID 43009023